Cited by 39Osteoarthritis Treatment and MechanismsProteoglycans and glycosaminoglycans researchHip disorders and treatments

Osteoarthritis Year in Review 2024: Molecular biomarkers of osteoarthritis

Open access
Welhaven, Hope D., Welfley, Avery H., June, Ronald K.·2025·Osteoarthritis and Cartilage

Abstract

Objective To provide a comprehensive and insightful summary of studies on molecular biomarkers at the gene, protein, and metabolite levels across different sample types and joints affected by osteoarthritis (OA). Methods A literature search using the PubMed database for publications on OA biomarkers published between April 1, 2023 and April 30, 2024 was performed. Publications were then screened, examined at length, and summarized in a narrative review. Results Out of the 364 papers initially identified, 44 publications met inclusion criteria, were relevant to OA, and were further examined for data extraction and discussion. These studies included 1 genomic analysis, 22 on protein markers, 6 on metabolite markers, 9 on inflammatory mediators, and 6 integrating multiple molecular levels. Conclusions Significant advancements have been made in identifying molecular biomarkers for OA, encompassing various joints, sample types, and molecular levels. Despite this progress, gaps remain, particularly in the need for validation, larger sample sizes, the integration of more clinical data, and consideration of covariates. For early detection and improved treatment of OA, continued efforts in biomarker identification are needed. This effort should seek to identify effective biomarkers that advance early detection, support prevention, evaluate interventions, and improve patient outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.joca.2024.10.003

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • High-throughput screening and single-cell analytics have transformed biomarker discovery for degenerative joint disease by enabling comprehensive molecular profiling across genomic, transcriptomic, proteomic, and metabolomic domains.

    “High-throughput screening and single-cell analytics have transformed biomarker discovery for degenerative joint disease by enabling comprehensive molecular profiling across genomic, transcriptomic, proteomic, and metabolomic domains”

    From Biomarker-Guided Imaging and AI-Augmented Diagnosis of Degenerative Joint Disease (2025) · cites this paper as [155]

    The Introduction and Discussion describe osteoarthritis biomarker research at gene, protein, and metabolite levels, and the Concluding Remarks say multi-omic studies show promise. But the copy does not attribute this progress to high-throughput screening or single-cell analytics, nor does it say those methods have transformed discovery or enabled comprehensive profiling across all four named domains. No page numbers were provided for these passages. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Longitudinal studies and standardization efforts enhance the clinical applicability of biomarkers for degenerative joint disease.

    “while longitudinal studies and standardization efforts enhance their clinical applicability [155].”

    From Biomarker-Guided Imaging and AI-Augmented Diagnosis of Degenerative Joint Disease (2025) · cites this paper as [155]

    The Discussion (Protein-level; page unavailable) describes a longitudinal study linking baseline biomarkers to later joint changes and their potential prognostic use. The Concluding Remarks (page unavailable) call for independent validation and larger cohorts to advance biomarkers toward clinical use, but do not specifically identify standardization efforts as a means of improving applicability. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 58 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [24]Chen X, Xu J, Zhang H, Yu L. A nomogram for predicting osteoarthritis based on serum biomarkers of bone turnover in middle age: A cross-sectional study of PTH and beta-CTx. Medicine (Baltimore) 2023; 102: e33833. 37335703 PMC10194786

Cited by

Sorted by citations

Authors
Welhaven, H. D., Welfley, A. H., & June, R. K.
Affiliations
Montana State University (US)
Corresponding author
June, Ronald K.
Venue
Osteoarthritis and Cartilage
Publisher
Elsevier BV
Published
2025-01
Volume
33
Issue
1
Pages
67-87
ISSN
1063-4584 (ISSN-L)
OpenAlex
W4403528140
Cited by
39
References
58
Citations by year
2026: 26 · 2025: 13
FWCI
2.90
Type
journal article
Language
en
Open access
Locations
  • Osteoarthritis and Cartilage (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • Montana State University ScholarWorks (Montana State University) (submittedVersion, cc-by-nc-nd)
Funders
  • National Science Foundation Division of Civil Mechanical and Manufacturing Innovation
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
Topics
  • Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Surgery › Hip disorders and treatments
Keywords
osteoarthritis, molecular biomarkers, protein biomarkers, metabolic biomarkers, genomic biomarkers, inflammatory mediators, early detection, biomarker validation, joint diseases
MeSH terms
Humans, Osteoarthritis, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review